Details of the Drug

General Information of Drug (ID: DMQYLGP)

• Drug Name: Levocetirizine
• Synonyms: (-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Seasonal allergic rhinitis	CA08.01	Approved	[1]

• Affected Organisms: Humans and other mammals
• ATC Code:
  R06AE09: Levocetirizine
  R06AE: Piperazine derivatives
  R06A: ANTIHISTAMINES FOR SYSTEMIC USE
  R06: ANTIHISTAMINES FOR SYSTEMIC USE
  R: RESPIRATORY SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 388.892
  Logarithm of the Partition Coefficient (xlogp); 1.7
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2.31 +/- 0.50 mgh/L [2]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 0.27 +/- 0.0 4 mg/L [2]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.75 +/- 0.50 h [2]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
  Clearance: The clearance of drug is 0.57 +/- 0.18 mL/min/kg [2]
  Elimination: 168 hours post dose an average of 85.4% of a radiolabeled dose was recovered with an average of 80.8% in the urine and 9.5% in the feces [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 7.05 +/- 1.54 hours [2]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1837 micromolar/kg/day [4]
  Vd: The volume of distribution (Vd) of drug is 0.33 +/- 0.02 L/kg [2]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.101 mg/mL [3]
• Chemical Identifiers:
  Formula: C21H25ClN2O3
  IUPAC Name: 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
  Canonical SMILES: C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
  InChI: InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
  InChIKey: ZKLPARSLTMPFCP-OAQYLSRUSA-N
• Cross-matching ID:
  PubChem CID: 1549000
  ChEBI ID: CHEMBL94559
  CAS Number: 130018-77-8
  UNII: 6U5EA9RT2O
  DrugBank ID: DB06282
  VARIDT ID: DR01302
• Drug Pharmacogenomic Perturbation (DPP)NEW: Click to Jump to the Detailed DPP Information of This Drug
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporter 4 (SLC22A11)	DT06JWZ	S22AB_HUMAN	Substrate	[5]

References

• [1] Levocetirizine FDA Label
• [2] Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol. 2001 Oct;57(8):571-82.
• [3] BDDCS applied to over 900 drugs
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.